Guido Kroemer, M.D., Ph.D.
Email:
kroemer(a)orange.fr
Institution:
University of Paris Descartes
Bio:
Prior to joining INSERM (1993), Dr. Kroemer was Senior Scientist of the European Community at the Spanish National Research Council (CSIC), at the National Center of Molecular Biology (1990-1992) and at the National Center of Biotechnology (1993). Dr. Kroemer did his post-doctoral training in the Collège de France, Nogent-sur-Marne (1988-1989) and at the University of Innsbruck, Austria, after receiving his Ph.D/M.D. degree at the same University in 1985. He also holds a Ph.D. degree in Biology (Autonomous University of Madrid, 1992). Dr. Kroemer has made important contributions to medical research through his groundbreaking work in the fields of cell biology and cancer research. He is best known for the discovery that the permeabilization of mitochondrial membranes constitutes a decisive step in programmed cell death. Kroemer has explored the fine mechanisms of mitochondrial cell death control, the molecular pathways that explain the inhibition of cell death in cancer cells, upstream of or at the level of mitochondria, and the mechanisms that make cancer cell death immunogenic. His work has had far reaching implications for the comprehension, detection and therapeutic manipulation of cellular demise.
Web Site:
http://www.kroemerlab.com/index.htm
Abstracts:
Aug 23, 2012 Cell Cycle. 2012 Aug 23;11(18). [Epub ahead of print]
Aug 15, 2012 Tetraploid cancer cell precursors in ovarian carcinoma.
Jul 23, 2012 Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein1, opposes to metastasis in pancreatic cancer.
Jul 1, 2012 Trial Watch: Immunostimulatory cytokines.
Jul 1, 2012 Abscopal but desirable: The contribution of immune responses to the efficacy ofradiotherapy.
Jun 8, 2012 When death was young: an ancestral apoptotic network in bacteria.
Jun 6, 2012 Multifaceted roles of purinergic receptors in viral infection.
Jun 1, 2012 Preferential killing of p53-deficient cancer cells by reversine.
May 31, 2012 Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens.
May 11, 2012 Autophagy mediates the metabolic benefits of endurance training.
May 1, 2012 Phosphoproteomic analysis of cells treated with longevity-related autophagyinducers.
May 1, 2012 Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer
May 1, 2012 Trial Watch: Adoptive cell transfer immunotherapy
May 1, 2012 Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer
May 1, 2012 Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39
May 1, 2012 Subversion of the chemotherapy-induced anticancer immune response by theecto-ATPase CD39.
May 1, 2012 Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer.
May 1, 2012 Trial Watch: Adoptive cell transfer immunotherapy.
May 1, 2012 Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response tochemotherapy in non-small cell lung cancer.
Apr 17, 2012 BH3-only proteins are part of a regulatory network that control the sustainedsignalling of the unfolded protein response sensor IRE1α
Apr 13, 2012 Expression of the P2X7 receptor increases in vivo tumor growth.
Mar 21, 2012 Selective killing of p53-deficient cancer cells by SP600125.
Mar 18, 2012 Inflammasomes in carcinogenesis and anticancer immune responses.
Mar 16, 2012 Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells.
Mar 15, 2012 Reverse Warburg: Straight to cancer.
Mar 9, 2012 Non-apoptotic functions of apoptosis-regulatory proteins.
Mar 6, 2012 Reply to: Chemotherapy response of spontaneous mammary tumors is independent ofthe adaptive immune system.
Mar 1, 2012 The European Academy of Tumor Immunology: Bridging fields, continents andgenerations.
Jan 17, 2012 Enlightening the impact of immunogenic cell death in photodynamic cancer therapy.
Jan 1, 2012 Evaluation of rapamycin-induced cell death.
Jan 1, 2012 The end of autophagic cell death?
Jan 1, 2012 Autophagy is required for the activation of NFkB.
Jan 1, 2012 Autophagic removal of micronuclei.
Jan 1, 2012 OncoImmunology: a new journal at the frontier between oncology and immunology
Jan 1, 2012 The fabulous legacy of a Nobel Prize Laureate: Ralph M. Steinman, 1943-2011
Jan 1, 2012 Trial Watch: Monoclonal antibodies in cancer therapy
Jan 1, 2012 Trial Watch: Monoclonal antibodies in cancer therapy.
Jan 1, 2012 OncoImmunology: a new journal at the frontier between oncology and immunology.
Dec 23, 2011 Necroptosis Turns TNF Lethal.
Dec 16, 2011 Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.
Dec 14, 2011 Defining the Critical Hurdles in Cancer Immunotherapy.
Nov 21, 2011 Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia.
Nov 11, 2011 Inhibition of autophagy by TAB2 and TAB3.
Oct 8, 2011 Critical Involvement of Extracellular ATP Acting on P2RX7 Purinergic Receptors in Photoreceptor Cell Death.
Sep 15, 2011 Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia
Sep 1, 2011 Prognostic and predictive impact of intra- and peritumoral immune infiltrates.
kroemer(a)orange.fr
Institution:
University of Paris Descartes
Bio:
Prior to joining INSERM (1993), Dr. Kroemer was Senior Scientist of the European Community at the Spanish National Research Council (CSIC), at the National Center of Molecular Biology (1990-1992) and at the National Center of Biotechnology (1993). Dr. Kroemer did his post-doctoral training in the Collège de France, Nogent-sur-Marne (1988-1989) and at the University of Innsbruck, Austria, after receiving his Ph.D/M.D. degree at the same University in 1985. He also holds a Ph.D. degree in Biology (Autonomous University of Madrid, 1992). Dr. Kroemer has made important contributions to medical research through his groundbreaking work in the fields of cell biology and cancer research. He is best known for the discovery that the permeabilization of mitochondrial membranes constitutes a decisive step in programmed cell death. Kroemer has explored the fine mechanisms of mitochondrial cell death control, the molecular pathways that explain the inhibition of cell death in cancer cells, upstream of or at the level of mitochondria, and the mechanisms that make cancer cell death immunogenic. His work has had far reaching implications for the comprehension, detection and therapeutic manipulation of cellular demise.
Web Site:
http://www.kroemerlab.com/index.htm
Abstracts:
Aug 23, 2012 Cell Cycle. 2012 Aug 23;11(18). [Epub ahead of print]
Aug 15, 2012 Tetraploid cancer cell precursors in ovarian carcinoma.
Jul 23, 2012 Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein1, opposes to metastasis in pancreatic cancer.
Jul 1, 2012 Trial Watch: Immunostimulatory cytokines.
Jul 1, 2012 Abscopal but desirable: The contribution of immune responses to the efficacy ofradiotherapy.
Jun 8, 2012 When death was young: an ancestral apoptotic network in bacteria.
Jun 6, 2012 Multifaceted roles of purinergic receptors in viral infection.
Jun 1, 2012 Preferential killing of p53-deficient cancer cells by reversine.
May 31, 2012 Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens.
May 11, 2012 Autophagy mediates the metabolic benefits of endurance training.
May 1, 2012 Phosphoproteomic analysis of cells treated with longevity-related autophagyinducers.
May 1, 2012 Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer
May 1, 2012 Trial Watch: Adoptive cell transfer immunotherapy
May 1, 2012 Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer
May 1, 2012 Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39
May 1, 2012 Subversion of the chemotherapy-induced anticancer immune response by theecto-ATPase CD39.
May 1, 2012 Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer.
May 1, 2012 Trial Watch: Adoptive cell transfer immunotherapy.
May 1, 2012 Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response tochemotherapy in non-small cell lung cancer.
Apr 17, 2012 BH3-only proteins are part of a regulatory network that control the sustainedsignalling of the unfolded protein response sensor IRE1α
Apr 13, 2012 Expression of the P2X7 receptor increases in vivo tumor growth.
Mar 21, 2012 Selective killing of p53-deficient cancer cells by SP600125.
Mar 18, 2012 Inflammasomes in carcinogenesis and anticancer immune responses.
Mar 16, 2012 Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells.
Mar 15, 2012 Reverse Warburg: Straight to cancer.
Mar 9, 2012 Non-apoptotic functions of apoptosis-regulatory proteins.
Mar 6, 2012 Reply to: Chemotherapy response of spontaneous mammary tumors is independent ofthe adaptive immune system.
Mar 1, 2012 The European Academy of Tumor Immunology: Bridging fields, continents andgenerations.
Jan 17, 2012 Enlightening the impact of immunogenic cell death in photodynamic cancer therapy.
Jan 1, 2012 Evaluation of rapamycin-induced cell death.
Jan 1, 2012 The end of autophagic cell death?
Jan 1, 2012 Autophagy is required for the activation of NFkB.
Jan 1, 2012 Autophagic removal of micronuclei.
Jan 1, 2012 OncoImmunology: a new journal at the frontier between oncology and immunology
Jan 1, 2012 The fabulous legacy of a Nobel Prize Laureate: Ralph M. Steinman, 1943-2011
Jan 1, 2012 Trial Watch: Monoclonal antibodies in cancer therapy
Jan 1, 2012 Trial Watch: Monoclonal antibodies in cancer therapy.
Jan 1, 2012 OncoImmunology: a new journal at the frontier between oncology and immunology.
Dec 23, 2011 Necroptosis Turns TNF Lethal.
Dec 16, 2011 Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.
Dec 14, 2011 Defining the Critical Hurdles in Cancer Immunotherapy.
Nov 21, 2011 Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia.
Nov 11, 2011 Inhibition of autophagy by TAB2 and TAB3.
Oct 8, 2011 Critical Involvement of Extracellular ATP Acting on P2RX7 Purinergic Receptors in Photoreceptor Cell Death.
Sep 15, 2011 Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia
Sep 1, 2011 Prognostic and predictive impact of intra- and peritumoral immune infiltrates.